Improve donor heart viability and decrease peri-operative costs with Asporto

Because heart transplantation patients are generally much healthier than other patients with end-stage heart failure, there is a significant decrease in medical costs one year after transplantation. This is then followed by relatively a constant annual expenditure from immunosuppression medications.

A cost analysis completed by Dr. Schnitzler at the St. Louis University School of Medicine determined that the additional value and quality of life year obtained with a heart transplant is worthy of an additional $500,000 invested per donor heart because the cost avoided by each additional patient removed from the waiting list is approximately $440,000.¹ He concluded that combining the social worth and the quality of life year obtained from heart transplantation for heart failure results in a better cost effectiveness than left ventricular assist device destination therapy or even medical management. This is because costs escalate at the end-of-life from intensive medical care (about $10,000/day). In the absence of another viable alternative, cardiac transplantation will never consume enormous resources as compared to other approaches to treating patients with end-stage diseases.²

Another problem with heart transplantation is rejection of the donor heart. Rejection depends upon tissue compatibility of the donor heart, ranked from 0 to 6 based upon tissue (mis)matching. If the tissue mismatches are 0 or 1 then the risk of rejection in the first year is 44%, this goes up to 65% when there are 5 or 6 mismatches.³ Based upon a current cost to treat rejection at $5,750, the total annual cost for poorly matched hearts is about $2.5 million.⁴

One of Hibernicor’s future objectives is to provide the necessary additional time to allow laboratory completion of tissue matching. This will provide patient’s with a better-matched heart, thus improving patient survival and reducing the cost of post transplant care from reduced rejection episodes.

References:

©2015 Hibernicor, LLC. All rights reserved. Hibernicor and Asporto are registered trademarks of Hibernicor, LLC in the USA and other countries. The contents herein are summary in nature and subject to change without notice.